Andre M. Mattman

Trained at UBC for medical school and medical biochemistry residency program. One year of research in mitochondrial disease at the Montreal Neurological Institute under direction of Dr Eric Shoubridge. Consultant at the Adult Metabolic Diseases Clinic at Vancouver General Hospital for 15 years. Chair of the Royal College national specialty committee in medical biochemistry for the past 6 years. Chair of the Provincial Laboratory Medicine Services chemistry advisory group for the past 5 years. Division Head of chemistry at St Paul's Chemistry since 2020.

Todd J. Anderson

Dr. Todd Anderson is a Professor of Cardiac Sciences at the University of Calgary. He is the former Head of the Department of Cardiac Sciences, and former Director of the Libin Cardiovascular Institute of Alberta. He has assumed a new role as the Vice Dean of the Cumming School of Medicine. His current research interests include the treatment of dyslipidemia and generation of lipid guidelines, the evaluation of appropriateness in clinical care delivery and the assessment of vascular function in health and disease particularly in women with microvascular angina.

Matthew P.A. Henderson, PhD, FCACB, FCCMG

Matthew Henderson is a Laboratory Head and Biochemist at Newborn Screening Ontario and an Assistant Professor in the Department of Pediatrics at the University of Ottawa, Canada. He is a fellow of the Canadian Academy of Clinical Biochemistry and the Canadian College of Medical Geneticists with a subspecialty in Laboratory Biochemical Genetics. His work is focused on improving the accuracy and efficiency of newborn screening through both development and optimization of biochemical assays as well as development of data analysis approaches and tools.

Raymond Lepage, Ph.D.

Raymond Lepage received a Ph.D. in Biochemistry in 1973 (U. de Montréal). He worked or directed thereafter multiple hospital and private laboratories. He was active in teaching in four different universities, authored or coauthored over 150 published manuscripts and abstracts and was on numerous meeting organization committees. He is a member of the CSCC since 1978 (president 2007-2008). He was very active in developing the first university based post-doctoral training program in clinical biochemistry in Quebec (1990). After retiring from the public sector in 2008, he joined a private laboratory and developed an expertise in Drug testing. He is now almost completely retired from the field and has kept only a part time activity as Scientific Writer.

Yiorgos Alexandros Cavayas

Dr. Cavayas is an Assistant Professor of Medicine at Université de Montréal, and Intensivist at the Hôpital Sacré-Coeur de Montréal, one of the busiest ICUs in the province of Quebec that has treated over 300 critically ill patients with COVID-19. Moreover, he is a clinician-investigator interested in severe acute respiratory failure and extracorporeal life support, currently conducting several observational and interventional studies on COVID-19.

Vincent De Guire
Julie Shaw

Dr Vincent De Guire is the chair of the CSCC SIG on Quality Improvement through QIs monitoring and the president of the Program for QIs comparison of the SQBC. He is notably a member of the WG Laboratory errors and patient safety and corresponding member of the committee Omic Translation of the IFCC. Dr De Guire also act as an expert on the WG on the pre-analytical phase of the EFLM.

Dr. Julie Shaw is the chair of the CSCC SIG for POCT and the CSCC representative on the IFCC POCT Working Group. She is the Regional Discipline Lead for Biochemistry and POCT at the Eastern Ontario Regional Laboratories Association.

Anna Füzéry

Dr. Anna Füzéry obtained her PhD in biochemistry from the University of Wisconsin in Madison, USA. She subsequently completed a 2-year postdoctoral fellowship program in clinical biochemistry at the Johns Hopkins Medical Institutes in Baltimore, USA. Upon completion of her training in 2013, she accepted a position as a clinical biochemist with Alberta Health Services in Edmonton, Canada. Her initial responsibilities included overseeing clinical biochemistry testing in 11 rapid response laboratories. In 2017 she transitioned into point-of-care testing (POCT) and became the medical lead for Edmonton followed by Northern Alberta. Dr. Füzéry is an associate clinical professor of laboratory medicine at the University of Alberta, and also co-directs the university’s Postdoctoral Clinical Biochemistry Fellowship program. Dr. Füzéry’s current research interests lie in enabling high quality, clinically relevant POCT in prehospital care and during critical care transport.

Mari DeMarco

Dr. Mari DeMarco is a Clinical Chemist at Providence Health Care, and a Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia in Vancouver, Canada. With a strong interest in bridging basic biomedical science, analytical chemistry and laboratory medicine, Dr. DeMarco’s research group focuses on building new biofluid tests for direct translation into patient care. A particular area of interest is advancing protein-based clinical diagnostics for neurodegenerative disorders, such as Alzheimer’s disease. The goal of this program of research is to ensure that these new tools make the challenging jump from research into healthcare.

Mark A. CervinskiPhD, DABCC

Mark Cervinski is the Director of Clinical Chemistry and Point-of-Care at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and Associate Professor of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth, in Hanover, New Hampshire.

Dr. Cervinski obtained his BS in Biology from the University of Mary, in Bismarck North Dakota, and his PhD in Biochemistry and Molecular Biology from the University of North Dakota School of Medicine and Health Science in 2006. Following the completion of his clinical chemistry fellowship at Washing University in St. Louis, Dr. Cervinski joined the Department of Pathology and Laboratory Medicine at the Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth.

Laura Smy

Laura Smy is an Assistant Professor at the tt/edical College of Wisconsin. ln this role, she provides direction for the chemistry and toxicology department, point-ofcare testing, and two small hospital laboratories within the Froedtert Health System. Her career working in a hospital laboratory, initially as a medical laboratory technologist, has fostered her interest in quality management and implementing concepts such as Six Sigma to provide the means for continual improvement in Iaboratory processes and assay results.

Lisa Johnson, PhD, DABCC

Dr. Johnson is a medical director in clinical chemistry at ARUP and an assistant professor in the Department of Pathology at the University of Utah in Salt Lake City. She specializes in esoteric testing that includes non-infectious gastrointestinal assays, advanced lipid analyses, and maternal serum screening. She received her doctorate in chemistry from the University of Wisconsin- Madison, performed post-doctoral research at UCLA, and completed her clinical chemistry fellowship training at the University of Minnesota.